Roche Names Teresa Graham Head of its Pharma Business
Teresa Graham, former Genentech executive and current Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO of Roche Pharmaceuticals, based in Basel, Switzerland, effective March 2023. She will also become a member of the Corporate Executive Committee.
Levi Garraway, Chief Medical Officer and Executive Vice President, Global Product Development, based in South San Francisco, will become a member of the enlarged Corporate Executive Committee. Both will report to the Roche Group CEO, Thomas Schinecker, who is replacing Severin Schwan as Roche's chief executive in March.
“I am excited that we can appoint a global strategic leader like Teresa Graham as our new Pharmaceuticals CEO. She brings a deep understanding of our business and is well-positioned for success.”
“Teresa Graham is a great leader with strong followership. She brings strategic and scientific acumen with an excellent track record of performance. I am pleased that a person of her caliber will be our new Pharma CEO," Mr. Schinecker said in a compay announcement. “Levi Garraway is an impressive clinician and scientist and I am excited to have him become a member of the Executive Committee. We remain intensely focused on our commitment to science and innovation – core tenets for ensuring a strong pipeline of medicines and our future success.”
Ms. Graham started with Genentech in 2005 in product management. She became a sales manager in 2010 before taking over the Marketing Director role for Rituxan Immunology and subsequently for Actemra. Her responsibilities further expanded in 2013 when she became Senior Director for Field Reimbursement Management and then Lifecycle Leader for Actemra. By 2017, she was leading major aspects of the portfolio for Genentech until she was appointed to her current role in 2019 and relocated to Basel, Switzerland.
Mr. Garraway joined Roche in October 2019 in his current role. Prior to entering the pharmaceutical industry, he was director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals including the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute of MIT and Harvard.